Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Cancer and Cardiac Ailments
4.2.2 Growing Awareness Regarding the Nuclear Medicine
4.3 Market Restraints
4.3.1 Short Half-Life of Radiopharmaceuticals
4.3.2 High capital investment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Alpha Emitters
5.1.1.1 Radium-223 (RA-223) & Alpharadin
5.1.1.2 Actinium-225 (AC-225)
5.1.1.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
5.1.1.4 Others
5.1.2 Beta Emitters
5.1.2.1 Iodine-131 (I-131)
5.1.2.2 Yttrium-90 (Y-90)
5.1.2.3 Others
5.1.3 Brachytherapy
5.1.3.1 Cesium-131
5.1.3.2 Iodine-125
5.1.3.3 Others
5.2 By Application
5.2.1 Oncology
5.2.2 Cardiology
5.2.3 Thyroid
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia- Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle- East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Actinium Pharmaceutical Inc.
6.1.2 Alpha Tau Medical Ltd
6.1.3 Bayer AG
6.1.4 Fusion Pharmaceuticals
6.1.5 IBA Radiopharma Solutions
6.1.6 RadioMedix Inc.
6.1.7 Telix Pharmaceuticals Ltd
6.1.8 NTP Radioisotopes
6.1.9 Triad Isotopes (Jubilant Life Sciences)


7 MARKET OPPORTUNITIES AND FUTURE TRENDS